Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-10
- Target Recruit Count
- 20
- Registration Number
- NCT06867432
Second-line Immunotherapy for ES-SCLC
Not Applicable
Recruiting
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Target Recruit Count
- 30
- Registration Number
- NCT06853678
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
The Importance of Thymus Anatomy to the Radical Resection of Thyroid Cancer Surgery and the Protection of Parathyroid Function
Not Applicable
Not yet recruiting
- Conditions
- Thyroid CancerSurgery
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Target Recruit Count
- 5
- Registration Number
- NCT06851260
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
Not Applicable
Not yet recruiting
- Conditions
- Brain MetastasisSRS
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Target Recruit Count
- 34
- Registration Number
- NCT06852001
Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
Phase 2
Recruiting
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc)Gall Bladder Cancer
- Interventions
- Drug: chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab.
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Target Recruit Count
- 33
- Registration Number
- NCT06852287
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tia, China
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Phase 2
Not yet recruiting
- Conditions
- Esophageal Squamour Cell Cancer
- Interventions
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-02-07
- Target Recruit Count
- 57
- Registration Number
- NCT06814158
- Locations
- 🇨🇳
Tianjin Medical University Cancer Hospital, Hexi District, Tianjin, China
Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Lung CancersRadiation Treatment for Tumors
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Target Recruit Count
- 84
- Registration Number
- NCT06775678
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
Phase 2
Recruiting
- Conditions
- Primary Liver Cancer
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-09
- Target Recruit Count
- 130
- Registration Number
- NCT06766643
- Locations
- 🇨🇳
Department of Hepatobiliary Oncology and Radiation Oncology,Tianjin Medical University Cancer Institute & Hospital,Key Laboratory of Cancer Prevention and Therapy,National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China
A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 21
- Registration Number
- NCT06760364
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 36
- Registration Number
- NCT06730659
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath